Table 2 Summary table of treatment and outcomes of our cohort
Patient | 1 | 2 | 3 | 4 | 5 | 6 |
|---|---|---|---|---|---|---|
Primary malignancy | Colorectal | Uterine sarcoma | Mesothelioma | Appendiceal | Ovarian | Mesothelioma |
Gender | F | F | M | F | F | F |
Age | 52 | 64 | 60 | 48 | 48 | 16 |
First CRS/HIPEC | ||||||
PCI score | 4 | 21 | 26 | 16 | 10 | 11 |
CC score | 0 | 0 | 0 | 0 | 0 | 0 |
Disease-free interval (DFI), (months) | 8 | 11 | 24 | 25 | 10 | 30 |
Interval between first and second CRS/HIPEC, (months) | 8 | 16 | 24 | 61 | 15 | 31 |
Second CRS/HIPEC | ||||||
PCI score | 7 | 27 | 22 | 39 | 20 | 11 |
CC score | 0 | 0 | 0 | 1 | 1 | 0 |
Disease-free interval (DFI) (months) | 25 | 4 | 5 | 30 | 10 | 33 |
Overall survival since initial CRS (months) | 71 | 39 | 69 | 151 | 48 | 64 |
Overall survival since second CRS (months) | 63 | 23 | 43 | 102 | 33 | 33 |
Total number of CRS/HIPEC | 3 | 2 | 2 | 3 | 2 | 2 |
Current status | Alive, stable disease under chemo therapy | Alive, disease regression under chemotherapy | Alive, progressive disease under chemotherapy | Alive, stable disease under chemotherapy | Alive, progressive disease under chemotherapy | Alive, no evidence of disease under chemotherapy |